# Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

> **NCT07325630** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- IBI363 + Chemotherapy

## Interventions

- **DRUG:** IBI363 + chemotherapy

## Key facts

- **NCT ID:** NCT07325630
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2026-05-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07325630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07325630, "Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07325630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*